CI · Q1 2026 Earnings

Cautious

Cigna

Reported April 30, 2026

30-second summary

Cigna raised the FY2026 adjusted EPS floor by $0.10 to ≥$30.35 and lifted the Cigna Healthcare segment income floor by $25M to ≥$4,525M, but the bigger disclosure is what was removed: the ~$280B FY revenue target, the ~$9.0B operating cash-flow guide, the ~5.0% adjusted SG&A guide, the ~19.0% tax-rate guide, and the ~18.1M medical-customer guide are all gone. Q1 MCR printed 79.8% — a full 390bps below the FY band ceiling of 84.7% and consistent with the "below 81%" Q1 frame — yet the FY MCR range was reaffirmed unchanged, signaling management still expects meaningful Q2–Q4 deterioration. The $0.10 EPS raise on the back of those withdrawals is the smallest possible affirmative gesture and should be read as such.

Headline numbers

EPS

Q1 FY2026

$7.79

Revenue

Q1 FY2026

$68.49B

+4.5% YoY

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$68.49B	+4.5%	$72.47B	-5.5%
EPS	$7.79	—	$8.08	-3.6%

Guidance

Cigna raised full-year EPS guidance by $0.10 to at least $30.35 on strong Q1 execution, but withdrew multiple supporting metrics including FY26 revenue, cash flow, and customer guidance.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted Income from Operations (per share)	FY 2026	at least $30.25	at least $30.35	+$0.10 per share	Raised
Cigna Healthcare Adjusted Income from Operations, Pre-Tax	FY 2026	at least $4,500 million	at least $4,525 million	+$25 million	Raised
Adjusted SG&A Expense Ratio	FY 2026	~5.0%	Withdrawn — no replacement	—	Withdrawn
Adjusted Effective Tax Rate	FY 2026	~19.0%	Withdrawn — no replacement	—	Withdrawn
Cash Flow from Operations	FY 2026	~$9,000 million	Withdrawn — no replacement	—	Withdrawn
Total Medical Customers	FY 2026	~18.1M	Withdrawn — no replacement	—	Withdrawn
Revenue	FY 2026	approximately $280.0 billion	Withdrawn — no replacement	—	Withdrawn

Reaffirmed unchanged this quarter: Evernorth Adjusted Income from Operations, Pre-Tax (at least $6,900 million), Cigna Healthcare Medical Care Ratio (83.7% to 84.7%)

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
Evernorth Health Services - Pharmacy Benefit Services	$33.002B	+10.9%
Evernorth Health Services - Specialty and Care Services	$25.44B	+6.3%
Cigna Healthcare	$11.477B	-20.8%

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
Total Medical Customers	18.334 million
Total Pharmacy Customers	121.020 million
Total Customer Relationships	185.470 million
Cigna Healthcare Medical Care Ratio	79.8%
Evernorth Adjusted Income from Operations Margin (Pre-Tax)	2.5%
Cigna Healthcare Adjusted Income from Operations Margin (Pre-Tax)	13.2%
SG&A Expense Ratio (GAAP)	5.4%
Adjusted SG&A Expense Ratio	4.8%

Management tone

Q2 selling-season confidence → Q3 2026 reset disclosure → Q4 quantified reset and CHC pivot → Q1 portfolio reshaping and disclosure pullback.

The narrative has shifted again. Through Q2–Q4 2025 management was defending an existing portfolio against cost-trend pressure and disclosing a quantified PBS reset; in Q1 the language pivots to "deliberate portfolio shaping" and "targeted innovation." The press-release quote anchors it: results were "driven by disciplined execution, deliberate portfolio shaping and targeted innovation." Two specific portfolio actions surfaced in the Q&A — exit of the individual exchange business and a strategic review of eviCore. On Bank of America's question, Brian Evanko framed both as proactive, not response-driven, with eviCore's review driven in part by industry standardization of prior authorization (a joint announcement on standardizing prior-auth information was referenced). This is a different posture than Q2's combative regulatory stance or Q3's defensive "we do not consciously write business at sustained losses."

Three quarters ago management was holding ten-plus FY metrics with quantified ranges; this quarter the company guides on per-share earnings and two segment income floors. Removing the ~$280B revenue target, ~$9.0B operating cash-flow guide, and the SG&A/tax-rate assumptions in a single quarter is not a routine refresh — it materially reduces the inputs investors need to triangulate the EPS bridge. Management did not address the removals on the print beyond the segment-and-per-share framing in the Goldman exchange. Signal: an active repositioning where the company prefers not to commit to consolidated metrics that may move with the portfolio.

The Signature model framing also hardened. At Q3 it was a 2028 standard with at-least-50% target by end-2028; at Q4 the timing was confirmed; in Q1's Q&A Brian Evanko added a guarantee — Signature delivers lowest out-of-pocket cost "30% lower than current" — and named "key new business wins already secured for 2027." From defense-of-existing-PBS in Q2 2025 to a quantified value proposition with secured 2027 wins in Q1 2026 is a 180-degree pivot in tone.

Q&A highlights

AJ Rice · UBS

How will clients transition to the new Signature PBM model launching in 2028? What lead time is required? When will management get client uptake indications? How much of the strong selling season is driven by Signature versus general market conditions?

Brian explained that Signature becomes the standard model in 2028 with at least 50% of PBS members expected in the model by year-end 2028. The 2027 selling season focuses on existing models with mid-90s+ retention expected. Key new business wins already secured for 2027. Market feedback on Signature has been positive, with clients appreciating the patient-centric, rebate-free approach and simplified economics. By year-end 2026, management will have better visibility on 2028 adoption levels.

Signature model launches in 2028Target: at least 50% of PBS members in Signature model by end of 20282027 selling season targeting mid-90s+ retentionEnded 2026 with over 97% retention

Kevin Fitchbeck · Bank of America

What is the capital impact from exiting the individual exchange business? Was the eviCore strategic review initiated by the company or in response to external interest? Is eviCore accretive or neutral economically?

Brian confirmed both portfolio actions (exchange exit and eviCore review) were proactive, disciplined decisions, not responses to external approaches. Exchange exit driven by inability to scale to meaningful size and management focus constraints; will free up some capital but not material. eviCore review driven by similar factors plus ongoing standardization/automation of prior authorization. No transaction to discuss; exploring strategic alternatives.

Individual exchange business is small and shrinkingCapital freed from exchange exit is not materialeviCore review is proactive strategic assessmentNo eviCore transaction currently in discussion

Lisa Gill · JP Morgan

How should we model the $150 million PBS cost run-rate from Q1 renewals and Signature transition investments throughout the rest of 2026? What are the key drivers of specialty business strength—is it existing client growth, volume, or biosimilar adoption?

Anne explained the $150 million quarterly headwind from renewals and Signature investments is consistent with prior guidance, with ramp-up weighted toward H2. Specialty strength driven by: (1) strong volume growth in core specialty pharmacy, (2) mix toward biosimilars and specialty generics providing cost savings, and (3) Shields contribution. Confident in delivering specialty at high end of growth range. PBS results in line with expectations.

PBS earnings down ~$150 million in Q1 vs. prior yearHeadwind reflects large client renewals and Signature transition investmentsInvestment ramp weighted toward H2 2026Specialty volume growth continued in Q1

Charles Rhee · TD Cowen

How much of specialty growth is driven by biosimilar adoption efforts and formulary changes? Can you discuss synergies across Evernorth businesses (e.g., biosimilar Stelara manufacturing through XCUR)? What is the outlook as more biosimilars enter the market?

Brian and David explained biosimilar/specialty generic adoption is critically important to affordability. Humira $0 copay penetration growing; Stelara $0 copay launched May 2024 showing nice growth in 10 months. Generic Amlodipine specialty generic expected to ease supply constraints. Also highlighted strong volume growth in severe asthma, hepatology, and fertility. David emphasized AI-driven personalized conversion strategies deliver high NPS, low friction, and strong physician coordination.

Humira biosimilar $0 copay program showing continued growthStelara biosimilar $0 copay launched May 2024, strong growth in 10 monthsGeneric Amlodipine specialty generic expected to ease supply constraintsSevere asthma volumes up with outsized percentage growth

Scott Seidel · Goldman Sachs

How do the announced portfolio actions (exchange exit, eviCore review) fit within the five historical growth pillars? What is your vision for continuity versus evolution of the growth strategy as you transition to CEO?

Brian outlined three core problem statements (affordability, fragmented experiences, reactive sick care) and three growth platforms: (1) specialty and care services (35% of income, 8-12% growth), (2) pharmacy benefit services (25% of income, transforming to Signature), (3) Cigna Healthcare (40% of income, flagship U.S. employer). Three areas of intensification: data/analytics/AI, affordability of care, upstream prevention. Three investor commitments: strong organic execution, disciplined capital deployment with portfolio shaping, significant equity appreciation potential.

Specialty and care services: 35% of company income, 8-12% annual growthPharmacy benefit services: 25% of company income, undergoing transformationCigna Healthcare: 40% of company income, U.S. employer flagshipThree intensification areas: data/AI/analytics, affordability, preventive care

Answers to last quarter's watch list

Q1 2026 Cigna Healthcare MCR landing point — Q1 printed 79.8%, comfortably inside the "below 81%" frame management gave at Q4 and 390bps below the FY ceiling of 84.7%. The FY 83.7%–84.7% band was reaffirmed unchanged, signaling management still expects meaningful seasonal deterioration through Q2–Q4.

Resolved positively

Evernorth PBS revenue and margin disclosure — PBS revenue grew +10.9% in Q1, decelerating sharply from Q4's +20% as contract repricing began flowing through. Evernorth segment pre-tax margin compressed to 2.5%, below FY2025's 3.1%. Management quantified the Q1 PBS EBIT headwind at roughly $150M with H2-weighted investment ramp. The FY Evernorth ≥$6,900M income floor was reaffirmed unchanged.

Resolved negatively

FY2026 EPS guide revision direction — Management raised the floor by $0.10 to ≥$30.35 — a +0.3% nudge that's directionally consistent with FY2025's hold-then-beat pattern but materially smaller in scale, and accompanied by the withdrawal of five supporting FY metrics. The raise alone is positive; the surrounding disclosure regression is not.

Resolved positively

Rebate-free model implementation cadence — Brian disclosed at-least-50% PBS member adoption by end-2028, mid-90s+ retention targeted for the 2027 selling season, key 2027 wins already secured, and a 30% lowest-out-of-pocket price guarantee. The strongest forward-disclosure on Signature to date.

Resolved positively

GPO tax structure execution — The ~19.0% adjusted effective tax-rate guide was withdrawn this quarter with no replacement disclosure. The Switzerland-to-U.S. GPO move wasn't called out on the print.

Not resolved

What to watch into next quarter

Whether the withdrawn metrics return at Q2 — If FY revenue, operating cash flow, SG&A, and tax-rate guides remain absent at Q2 it signals a structural shift in disclosure framework rather than a one-quarter pause tied to in-flight portfolio moves. Watch the Q2 release for any re-establishment of these guides.

Q2 Cigna Healthcare MCR vs. the FY band — Q1 at 79.8% sets up the seasonal climb. Watch whether Q2 MCR lands inside the typical mid-quarter zone for the 83.7%–84.7% FY band; a Q2 print above ~84% would call the reaffirmed FY range into question early.

eviCore review outcome — Management characterized the review as proactive with no transaction in discussion. Watch for any disclosure of perimeter, divestiture proceeds, or accretion/dilution math on the Q2 call.

Signature 2027 selling-season conversion — Watch for named 2027 wins beyond the unspecified count Brian referenced, retention confirmation in the mid-90s+ range, and any update on the at-least-50% PBS-member 2028 adoption target.

Evernorth segment pre-tax margin Q2 trajectory — Q1 at 2.5% is below FY2025's 3.1%; the disclosed H2-weighted investment ramp implies Q2 also runs below FY2025 levels. Watch whether segment margin holds at or above the Q1 2.5% level or compresses further as the ramp accelerates.

Sources

Cigna Q1 2026 press release (SEC EX-99.1): https://www.sec.gov/Archives/edgar/data/1739940/000114036126017971/ef20071317_ex99-1.htm
Cigna Q1 2026 earnings call Q&A excerpts

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.